Association between EGFR expression and clinical outcome of laryngeal HPV squamous cell carcinoma

Kontić, Mirko; Čolović, Zaviša; Paladin, Ivan; Gabelica, Mirko; Barić, Ana; Pešutić-Pisac, Valdi

doi:10.1080/00016489.2019.1651938

Cited by 8 publications

(8 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The relationship between both biomarkers in lung cancer has been less reported. Nevertheless, inconsistent findings in head and neck cancers have been obtained regarding the correlation, with a strong association found between HPV infections and EGFR expression in laryngeal squamous cell carcinoma [ 31 ], and a strong correlation with phosphorylated EGFR expression in HPV-negative tonsillar squamous cell carcinoma [ 32 ]. The prognostic value of HPV infection and EGFR expression in head and neck cancers has been reported as HPV infections on the survival outcomes are identified as a better prognostic factor [ 33 , 34 ], and phosphorylated EGFR is associated with longer survival and as a potential therapeutic biomarker [ 35 ].…”

Section: Discussionmentioning

confidence: 99%

Human Papillomavirus Oncoproteins Confer Sensitivity to Cisplatin by Interfering with Epidermal Growth Factor Receptor Nuclear Trafficking Related to More Favorable Clinical Survival Outcomes in Non-Small Cell Lung Cancer

Wang

Lee

Fang

et al. 2022

Cancers

View full text Add to dashboard Cite

High-risk human papillomavirus (HPV) infections and epidermal growth factor receptor (EGFR) expression have been reported to be associated with more favorable survival outcomes in lung adenocarcinoma patients. In this study, we utilized transfected HPV 16E5/16E6/16E7 H292 cells to investigate the mechanism of HPV oncoproteins interfering with EGFR nuclear trafficking related to a better response to cisplatin. Furthermore, we correlated HPV 16E6/18E6 expression and differentially localized EGFR expression with the clinical association and survival impact in lung adenocarcinoma patients. Our results found significantly higher phosphorylated nuclear EGFR expression upon epidermal growth factor stimulus and better responses to cisplatin in transfected HPV 16E5/16E6/16E7 NCI-H292 cells and xenograft animal models. Our data were compatible with clinical results of a high correlation of HPV 16E6/18E6 and EGFR expression in non-small cell lung cancer tissues and the synergistic effects of both with the best survival prognosis in a lung adenocarcinoma cohort, especially in patients with older age, no brain metastasis, smoking history, and wild-type EGFR status. Cumulatively, our study supports HPV 16E5/16E6/16E7 oncoproteins interfering with EGFR nuclear trafficking, resulting in increased sensitivity to cisplatin. HPV 16E6/18E6 and EGFR expression serve as good prognostic factors in lung adenocarcinoma patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Human Papillomavirus Oncoproteins Confer Sensitivity to Cisplatin by Interfering with Epidermal Growth Factor Receptor Nuclear Trafficking Related to More Favorable Clinical Survival Outcomes in Non-Small Cell Lung Cancer

Wang

Lee

Fang

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Conversely, it has been reported that the expression of EGFR can be negatively regulated by the methylation of its promoter, which is more often associated with HPV infection ( 24 ). In this regard, it is of note that HPV-positive HNSCCs have a tendency to express lower levels of EGFR as compared to HPV-negative tumors ( 29 , 52 , 69 , 70 ). On the other hand, as regards the impact of HPV status on the expression levels of ErbB receptors, HPV-positive HNSCC have been found to express higher levels of ErbB2, ErbB3 and ErbB2:ErbB3 heterodimers as compared to HPV-negative tumors ( 70 ).…”

Section: Aberrant Expression Of Erbb Receptors In Hnsccmentioning

confidence: 99%

“…Even though HPV-positive HNSCCs have a tendency to express lower levels of EGFR, according to some authors this receptor holds prognostic value also in this subgroup of tumors. In fact, it has been reported that the outcome of HPV-positive tumors with higher EGFR levels is worse as compared to that of HPV-positive tumors with low EGFR ( 29 , 52 , 69 ). However, others reported that the impact of EGFR on outcome may be limited to HPV-negative HNSCCs ( 32 , 79 ).…”

Section: Erbb Receptors and Prognosis Of Hnsccmentioning

confidence: 99%

Recent findings on the impact of ErbB receptors status on prognosis and therapy of head and neck squamous cell carcinoma

et al. 2023

View full text Add to dashboard Cite

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer type, has often an aggressive course and is poorly responsive to current therapeutic approaches, so that 5-year survival rates for patients diagnosed with advanced disease is lower than 50%. The Epidermal Growth Factor Receptor (EGFR) has emerged as an established oncogene in HNSCC. Indeed, although HNSCCs are a heterogeneous group of cancers which differ for histological, molecular and clinical features, EGFR is overexpressed or mutated in a percentage of cases up to about 90%. Moreover, aberrant expression of the other members of the ErbB receptor family, ErbB2, ErbB3 and ErbB4, has also been reported in variable proportions of HNSCCs. Therefore, an increased expression/activity of one or multiple ErbB receptors is found in the vast majority of patients with HNSCC. While aberrant ErbB signaling has long been known to play a critical role in tumor growth, angiogenesis, invasion, metastatization and resistance to therapy, more recent evidence has revealed its impact on other features of cancer cells’ biology, such as the ability to evade antitumor immunity. In this paper we will review recent findings on how ErbB receptors expression and activity, including that associated with non-canonical signaling mechanisms, impacts on prognosis and therapy of HNSCC.

show abstract

“…mEGFR protein expression was assessed according to the following scoring approach: 0 (no immunoreactivity or immunoreactivity in <10% of cells), 1+ (faint weak and incomplete staining in > 10% of cells), 2+ (weak to moderate complete membrane immunoreactivity in > 10% of cells), and 3+ (strong complete membrane immunoreactivity in > 10% of cells). 18 nEGFR protein expression was evaluated and ranked into 4 groups according to the percentage of the positive cells: strong (3+, > 35%), moderate (2+, 18% to 35%), weak (1+, 1% to 17%), and negative (−, 0%). 6 For subsequent clinicopathologic associations and survival statistical analyses nEGFR and mEGFR were graded as weak expression if staining was 0/1+/2++ and strong if staining was 3+.…”

Section: Immunohistochemical Scoringmentioning

confidence: 99%

Nuclear EGFR Expression Is Associated With Poor Survival in Laryngeal Carcinoma

Marijić¹,

Braut²,

Babarović

et al. 2021

Applied Immunohistochemistry &Amp; Molecular Morphology

View full text Add to dashboard Cite

show abstract

Association between EGFR expression and clinical outcome of laryngeal HPV squamous cell carcinoma

Cited by 8 publications

References 14 publications

Human Papillomavirus Oncoproteins Confer Sensitivity to Cisplatin by Interfering with Epidermal Growth Factor Receptor Nuclear Trafficking Related to More Favorable Clinical Survival Outcomes in Non-Small Cell Lung Cancer

Human Papillomavirus Oncoproteins Confer Sensitivity to Cisplatin by Interfering with Epidermal Growth Factor Receptor Nuclear Trafficking Related to More Favorable Clinical Survival Outcomes in Non-Small Cell Lung Cancer

Recent findings on the impact of ErbB receptors status on prognosis and therapy of head and neck squamous cell carcinoma

Nuclear EGFR Expression Is Associated With Poor Survival in Laryngeal Carcinoma

Contact Info

Product

Resources

About